HC Wainwright & Co. Maintains Buy on Compass Therapeutics, Lowers Price Target to $12

Benzinga Newsdesk www.benzinga.com Negative 46.7%

Neg 46.7% Neu 0% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $24 to $12.